Evidence map›Paper›PMID 29940877›Full record

ArticleBMC nephrology2018

Hematuria as a risk factor for progression of chronic kidney disease and death: findings from the Chronic Renal Insufficiency Cohort (CRIC) Study.

Paula F Orlandi, Naohiko Fujii, Jason Roy, Hsiang-Yu Chen, L Lee Hamm, James H Sondheimer, Jiang He, Michael J Fischer, Hernan Rincon-Choles, Geetha Krishnan and 7 more

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in BMC nephrology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 2 pooled it
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 49 citations in OpenAlex.

  1. Pooled it
  2. Chronic kidney disease and risk of kidney or urothelial malignancy: systematic review and meta-analysis.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2024
    Pooled it
  3. Review
  4. Article
  5. [Progression inhibition in chronic kidney disease].Innere Medizin (Heidelberg, Germany) · 2026
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 2 countries.

Paula F OrlandiCenter for Clinical Epidemiology and Biostatistics, University of Pennsylvania, 824 Guardian Drive, Blockley Hall, Philadelphia, Pennsylvania, 19104-6021, USA. orlandip@pennmedicine.upenn.edu.ORCID 0000-0002-7099-9345
Naohiko FujiiHyogo Prefectural Nishinomiya Hospital, Hyogo, Japan.
Jason RoyCenter for Clinical Epidemiology and Biostatistics, University of Pennsylvania, 824 Guardian Drive, Blockley Hall, Philadelphia, Pennsylvania, 19104-6021, USA.
Hsiang-Yu ChenCenter for Clinical Epidemiology and Biostatistics, University of Pennsylvania, 824 Guardian Drive, Blockley Hall, Philadelphia, Pennsylvania, 19104-6021, USA.
L Lee HammSchool of Medicine, Tulane University School of Medicine, New Orleans, Louisiana, USA.
James H SondheimerSchool of Medicine, Wayne State University, Detroit, Michigan, USA.
Jiang HeSchool of Medicine, Tulane University School of Medicine, New Orleans, Louisiana, USA.
Michael J FischerMedicine Service, Jesse Brown VA Medical Center, Chicago, Illinois, USA.
Hernan Rincon-CholesCleveland Clinic Foundation, Case Western Reserve University, Cleveland, Ohio, USA.
Geetha KrishnanCleveland Clinic Foundation, Case Western Reserve University, Cleveland, Ohio, USA.
Raymond TownsendDepartment of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Tariq ShafiJohn Hopkins University, School of Medicine, Baltimore, Maryland, USA.
Chi-Yuan HsuSchool of Medicine, University of California, San Francisco, California, USA.
John W KusekNational Institutes of Health, Bethesda, Maryland, USA.
John T DaugirdasRenal Division, University of Illinois Hospital and Health Sciences Center, Chicago, Illinois, USA.
Harold I FeldmanCenter for Clinical Epidemiology and Biostatistics, University of Pennsylvania, 824 Guardian Drive, Blockley Hall, Philadelphia, Pennsylvania, 19104-6021, USA.
CRIC Study Investigators
Tulane University · USUniversity of Pennsylvania · USCleveland Clinic · USHyogo Prefectural Nishinomiya Hospital · JPNational Institutes of Health · USUniversity of California, San Francisco · USUniversity of Illinois Chicago · US

Funding

UCSF CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR024131 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOHNSTON, S. CLAIBORNE · 2006 to 2011
$111.2M
Scientific and Data Coordinating Center(SDCC) for the P*U01DK060990 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI FELDMAN, HAROLD I · 2001 to 2017
$50.1M
Clinical and Translational Science Collaborative of ClevelandUL1TR000439 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI KONSTAN, MICHAEL W. · 2012 to 2016
$50.0M
Michigan Institute for Clinical and Health Research (MCHR)UL1TR000433 · NCATS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MASHOUR, GEORGE ALEXANDER · 2012 to 2016
$49.9M
Institutional Clinical and Translational Science AwardUL1TR000003 · NCATS · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 2012 to 2015
$38.9M
Strengthening Stakeholder Engagement in Human Research Protections.UL1TR002003 · NCATS · UNIVERSITY OF ILLINOIS AT CHICAGO · PI KARNIK, NIRANJAN SUBHASH, MERMELSTEIN, ROBIN J. · 2016 to 2024
$33.7M
Tulane COBRE in Cardiometabolic Diseases Clinical Research CoreP20GM109036 · NIGMS · TULANE UNIVERSITY OF LOUISIANA · PI Katherine Teresa Mills · 2016 to 2026
$25.3M
Continuation of the Coordinating Center for the Chronic Renal Insufficiency Cohort (CRIC) StudyU24DK060990 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI Amanda Hyre Anderson, Laura M Dember · 2018 to 2026
$21.5M
Zonulin Antibodies in Intestinal Permeabilitiy in IDDMM01RR016500 · NCRR · UNIVERSITY OF MARYLAND BALTIMORE · PI EDELMAN, MARTIN J. · 2002 to 2009
$20.2M
Study of the Care and Outcomes of REnal InsufficiencyU01DK060902 · NIDDK · KAISER FOUNDATION RESEARCH INSTITUTE · PI GO, ALAN S · 2001 to 2025
$19.5M
Limited Competition for the Continuation of the Chronic Renal Insufficiency CohorU01DK061021 · NIDDK · CASE WESTERN RESERVE UNIVERSITY · PI RAHMAN, MAHBOOB · 2001 to 2025
$17.3M
Prospective Renal Insufficiency Cohort Evaluation:PRICEU01DK060984 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI COHEN, DEBBIE L · 2001 to 2025
$17.0M
NCATS NIH HHS UL1 TR000003NCATS NIH HHS UL1 TR000424NCATS NIH HHS UL1 TR000433NCATS NIH HHS UL1TR000433NCATS NIH HHS UL1 TR000439NCATS NIH HHS UL1 TR002003NCRR NIH HHS M01 RR016500NCRR NIH HHS UL1 RR024131NCRR NIH HHS UL1 RR029879NIDDK NIH HHS R01 DK139225NIDDK NIH HHS U01 DK060902NIDDK NIH HHS U01 DK060963NIDDK NIH HHS U01 DK060980NIDDK NIH HHS U01 DK060984NIDDK NIH HHS U01 DK060990NIDDK NIH HHS U01 DK061021NIDDK NIH HHS U01 DK061022NIDDK NIH HHS U01 DK061028NIDDK NIH HHS U24 DK060990NIGMS NIH HHS P20 GM109036
6 · The paper itself

Abstract

backgroundHematuria is associated with chronic kidney disease (CKD), but has rarely been examined as a risk factor for CKD progression. We explored whether individuals with hematuria had worse outcomes compared to those without hematuria in the CRIC Study.

methodsParticipants were a racially and ethnically diverse group of adults (21 to 74 years), with moderate CKD. Presence of hematuria (positive dipstick) from a single urine sample was the primary predictor. Outcomes included a 50% or greater reduction in eGFR from baseline, ESRD, and death, over a median follow-up of 7.3 years, analyzed using Cox Proportional Hazards models. Net reclassification indices (NRI) and C statistics were calculated to evaluate their predictive performance.

resultsHematuria was observed in 1145 (29%) of a total of 3272 participants at baseline. Individuals with hematuria were more likely to be Hispanic (22% vs. 9.5%, respectively), have diabetes (56% vs. 48%), lower mean eGFR (40.2 vs. 45.3 ml/min/1.73 m2), and higher levels of urinary albumin > 1.0 g/day (36% vs. 10%). In multivariable-adjusted analysis, individuals with hematuria had a greater risk for all outcomes during the first 2 years of follow-up: Halving of eGFR or ESRD (HR Year 1: 1.68, Year 2: 1.36), ESRD (Year 1: 1.71, Year 2: 1.39) and death (Year 1:1.92, Year 2: 1.77), and these associations were attenuated, thereafter. Based on NRIs and C-statistics, no clear improvement in the ability to improve prediction of study outcomes was observed when hematuria was included in multivariable models.

conclusionIn a large adult cohort with CKD, hematuria was associated with a significantly higher risk of CKD progression and death in the first 2 years of follow-up but did not improve risk prediction.

Indexed as

Disease ProgressionAdultAgedCohort StudiesFemaleHematuriaHumansKidney Failure, ChronicMaleMiddle AgedMortalityProspective StudiesRenal Insufficiency, ChronicRisk FactorsCKDCKD progressionEpidemiologyESRDHematuriaMortalityRisk factors

Identifiers

PMID29940877
PMCPMC6020240
OpenAlexW2811359623

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.